As recently reviewed [80], a primary rationale for testing LSD1 inhibitors, such as ORY-1001, in preclinical models of neurodevelopmental and psychiatric disorders stems from observations of reduced H3K4me2 and/or H3K4me3 methylation in the brains of individuals with schizophrenia and ASD [41, 81, 82]. Here, KDM1A is linked to schizophrenia.